Cytosorbents Corporation (CTSO)

Market Cap	64.38M
Revenue (ttm)	35.59M
Net Income (ttm)	-20.72M
Shares Out	62.50M
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,720
Open	1.020
Previous Close	1.020
Day's Range	1.020 - 1.020
52-Week Range	0.700 - 1.610
Beta	1.17
Analysts	Strong Buy
Price Target	4.67 (+353.4%)
Earnings Date	May 8, 2025

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. It’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as sev...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 149
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO
• Website: https://www.cytosorbents.com

Financial Performance

In 2024, Cytosorbents's revenue was $35.59 million, an increase of 14.51% compared to the previous year's $31.08 million. Losses were -$20.72 million, -29.16% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for CTSO stock is "Strong Buy." The 12-month stock price forecast is $4.67, which is an increase of 353.40% from the latest price.

Price Target

$4.67

(353.40% upside)

Analyst Consensus: Strong Buy